儿童炎症性肠病艰难梭菌感染及其易感因素分析

doi:10.7499/j.issn.1008-8830.2103129

摘要
图/表
参考文献(25)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (1094 KB) HTML()
输出: BibTeX | EndNote (RIS) 背景资料

摘要

目的了解儿童炎症性肠病（inflammatory bowel disease，IBD）中艰难梭菌定植及感染的发生率，评估儿童IBD患者发生艰难梭菌感染（Clostridium difficile infection，CDI）的易感因素。方法选取62例确诊IBD患儿为IBD组，选择同期因迁延性或慢性腹泻就诊并排除IBD的儿童42例为非IBD组，比较两组CDI情况；根据是否合并CDI将IBD组分为IBD合并CDI组（n=12）和IBD无CDI组（n=50），收集两组患儿相关临床资料行CDI易感因素分析。结果 IBD组CDI发生率为19%（12/62），高于非IBD组（2%，1/42）（P < 0.05）。IBD合并CDI组病程长于IBD无CDI组（P < 0.05），发热、腹泻、腹痛比例高于IBD无CDI组（P < 0.05）。IBD合并CDI组儿童克罗恩病活动指数、C反应蛋白、红细胞沉降率高于IBD无CDI组（P < 0.05）。单因素分析显示，IBD合并CDI组疾病严重程度（中重度）、使用激素、诊断前接受广谱抗生素治疗14 d以上比例高于IBD无CDI组（P < 0.05）。结论 IBD患儿CDI发生率较非IBD儿童高。病情越严重、使用广谱抗生素及激素可能导致IBD患儿更易发生CDI。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张文婷
	赵红梅
	罗艳红
	段佳琪
	李灿琳
	游洁玉

关键词 ：炎症性肠病, 艰难梭菌感染, 易感因素, 儿童

Abstract：Objective To investigate the incidence rates of Clostridium difficile colonization and Clostridium difficile infection (CDI) in children with inflammatory bowel disease (IBD) and the susceptibility factors for CDI in children with IBD. Methods A total of 62 children diagnosed with IBD were enrolled as the IBD group. Forty-two children who attended the hospital due to persistent or chronic diarrhea and were excluded from IBD were enrolled as the non-IBD group. The incidence rate of CDI was compared between the two groups. According to the presence or absence of CDI, the IBD group was subdivided into two groups:IBD+CDI (n=12) and non-CDI IBD (n=50), and the clinical data were collected from the two groups to analyze the susceptibility factors for CDI. Results The IBD group had a significantly higher incidence rate of CDI[19% (12/62) vs 2% (1/42); P < 0.05] than the non-IBD group (P < 0.05). Compared with the non-CDI IBD group, the IBD+CDI group had a significantly longer disease course (P < 0.05), and a significantly higher proportion of children with fever, diarrhea, or abdominal pain (P < 0.05). The IBD+CDI group had significantly higher activity indices of pediatric Crohn's disease, C-reactive protein levels and erythrocyte sedimentation rate than the non-CDI IBD group (P < 0.05). The univariate analysis showed that compared with the non-CDI IBD group, the IBD+CDI group had a significantly higher proportion of children with moderate-to-severe disease, use of glucocorticoids, or treatment with broad-spectrum antibiotics for more than 14 days before diagnosis (P < 0.05). Conclusions The children with IBD have a higher incidence of CDI than those without IBD. Severe disease conditions and use of broad-spectrum antibiotics or glucocorticoids may be associated with an increased incidence of CDI in children with IBD.

Key words： Inflammatory bowel disease Clostridium difficile infection Susceptibility factor Child

收稿日期: 2021-03-21

通讯作者: 游洁玉,女,主任医师。Email:yjy660111@sina.com。 E-mail: yjy660111@sina.com

作者简介: 张文婷,女,硕士研究生,主治医师。

引用本文:

张文婷,赵红梅,罗艳红等. 儿童炎症性肠病艰难梭菌感染及其易感因素分析[J]. 中国当代儿科杂志, 2021, 23(7): 718-723.

ZHANG Wen-Ting,ZHAO Hong-Mei,LUO Yan-Hong et al. Clostridium difficile infection and its susceptibility factors in children with inflammatory bowel disease[J]. CJCP, 2021, 23(7): 718-723.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2103129 或 http://www.zgddek.com/CN/Y2021/V23/I7/718

[1]	Ng SC. Emerging leadership lecture:inflammatory bowel disease in Asia:emergence of a "Western" disease[J]. J Gastroenterol Hepatol, 2015, 30(3):440-445. DOI:10.1111/jgh.12859. PMID:25469874.
[2]	Chou JW, Lai HC, Chang CH, et al. Epidemiology and clinical outcomes of inflammatory bowel disease:a hospital-based study in Central Taiwan[J]. Gastroenterol Res Pract, 2019, 2019:4175923. DOI:10.1155/2019/4175923. PMID:31312216. PMCID:PMC6595318.
[3]	Su HJ, Chiu YT, Chiu CT, et al. Inflammatory bowel disease and its treatment in 2018:global and Taiwanese status updates[J]. J Formos Med Assoc, 2019, 118(7):1083-1092. DOI:10.1016/j.jfma.2018.07.005. PMID:30054112.
[4]	D'Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection[J]. World J Gastroenterol, 2017, 23(27):4986-5003. DOI:10.3748/wjg.v23.i27.4986. PMID:28785153. PMCID:PMC5526769.
[5]	林赛争, 蔡建庭, 陈焰, 等. 难治性炎症性肠病患者艰难梭状芽胞杆菌感染流行病学及临床特征[J]. 中华医院感染学杂志, 2017, 27(10):2173-2176. DOI:10.11816/cn.ni.2017-170024.
[6]	Gómez S, Chaves F, Orellana MA. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection[J]. Anaerobe, 2017, 48:147-151. DOI:10.1016/j.anaerobe.2017.08.012. PMID:28830842.
[7]	Kim DH, Cho JM, Yang HR. Clostridium difficile infection at diagnosis and during the disease course of pediatric inflammatory bowel disease[J]. Pediatr Gastroenterol Hepatol Nutr, 2018, 21(1):43-50. DOI:10.5223/pghn.2018.21.1.43. PMID:29383304. PMCID:PMC5788950.
[8]	Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States[J]. N Engl J Med, 2015, 372(9):825-834. DOI:10.1056/NEJMoa1408913. PMID:25714160.
[9]	Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease[J]. Dig Dis Sci, 2014, 59(9):2222-2227. DOI:10.1007/s10620-014-3169-4. PMID:24788321.
[10]	Schutze GE, Willoughby RE, Committee on Infectious Diseases, et al. Clostridium difficile infection in infants and children[J]. Pediatrics, 2013, 131(1):196-200. DOI:10.1542/peds.2012-2992. PMID:23277317.
[11]	Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease:understanding the evolving relationship[J]. World J Gastroenterol, 2010, 16(39):4892-4904. DOI:10.3748/wjg.v16.i39.4892. PMID:20954275. PMCID:PMC2957597.
[12]	顾克菊, 胡必杰. 美国医院流行病学会和感染性疾病协会成人艰难梭菌感染临床指南(2010)摘译[J]. 中国感染控制杂志, 2011, 10(4):316-318. DOI:10.3969/j.issn.1671-9638.2011.04.026.
[13]	Turner D, Griffiths AM, Walters TD, et al. Appraisal of the Pediatric Crohn's Disease Activity Index on four prospectively collected datasets:recommended cutoff values and clinimetric properties[J]. Am J Gastroenterol, 2010, 105(9):2085-2092. DOI:10.1038/ajg.2010.143. PMID:20372111.
[14]	Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a Pediatric Ulcerative Colitis Activity Index:a prospective multicenter study[J]. Gastroenterology, 2007, 133(2):423-432. DOI:10.1053/j.gastro.2007.05.029. PMID:17681163.
[15]	Sokol H, Jegou S, McQuitty C, et al. Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection[J]. Gut Microbes, 2018, 9(1):55-60. DOI:10.1080/19490976.2017.1361092. PMID:28786749. PMCID:PMC5914915.
[16]	Wultańska D, Banaszkiewicz A, Radzikowski A, et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease[J]. Eur J Clin Microbiol Infect Dis, 2010, 29(10):1265-1270. DOI:10.1007/s10096-010-0997-9. PMID:20577773. PMCID:PMC2937146.
[17]	Markowitz JE, Brown KA, Mamula P, et al. Failure of single-toxin assays to detect Clostridium difficile infection in pediatric inflammatory bowel disease[J]. Am J Gastroenterol, 2001, 96(9):2688-2690. DOI:10.1111/j.1572-0241.2001.04125.x. PMID:11569696.
[18]	Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease[J]. J Pediatr, 2009, 154(6):854-858. DOI:10.1016/j.jpeds.2008.12.039. PMID:19230908.
[19]	Sokol H, Lalande V, Landman C, et al. Clostridium difficile infection in acute flares of inflammatory bowel disease:a prospective study[J]. Dig Liver Dis, 2017, 49(6):643-646. DOI:10.1016/j.dld.2017.01.162. PMID:28215602.
[20]	Erb S, Frei R, Strandén AM, et al. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients[J]. Clin Microbiol Infect, 2015, 21(11):998.e9-998.e15. DOI:10.1016/j.cmi.2015.07.016. PMID:26232535.
[21]	Balram B, Battat R, Al-Khoury A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease:a systematic review and meta-analysis[J]. J Crohns Colitis, 2019, 13(1):27-38. DOI:10.1093/ecco-jcc/jjy143. PMID:30247650.
[22]	Hourigan SK, Chirumamilla SR, Ross T, et al. Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2013, 19(13):2744-2752. DOI:10.1097/01.MIB.0000435434.53871.36. PMID:24145927.
[23]	Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microbe, 2014, 15(3):382-392. DOI:10.1016/j.chom.2014.02.005. PMID:24629344. PMCID:PMC4059512.
[24]	Hung YP, Lee JC, Tsai BY, et al. Risk factors of Clostridium difficile-associated diarrhea in hospitalized adults:vary by hospitalized duration[J]. J Microbiol Immunol Infect, 2021, 54(2):276-283. DOI:10.1016/j.jmii.2019.07.004. PMID:31522990.
[25]	Kariv R, Navaneethan U, Venkatesh PG, et al. Impact of Clostridium difficile infection in patients with ulcerative colitis[J]. J Crohns Colitis, 2011, 5(1):34-40. DOI:10.1016/j.crohns. 2010.09.007. PMID:21272802.